Daichii Sankyo's CFO Koji Ogawa tells CNBC's Squawk Box Asia what the pharma company is doing to mitigate the effects of U.S.

Researchers from the Japan Advanced Institute of Science and Technology, in collaboration with Daiichi Sankyo and the ...

A joint research team led by Professor Eijiro Miyako of the Japan Advanced Institute of Science and Technology (JAIST), in ...

See the latest Daiichi Sankyo Co Ltd stock price (4568:XTKS), related news, valuation, dividends and more to help you make your investing decisions.

Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and com ...

Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2023, it had a debt/adjusted EBITDA ratio of 0.42 times and over JPY 1.2 trillion in ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease ...

Three years earlier, Daiichi Sanko snapped up Germany’s U3 Pharma for €150 million ($235 million at the time but $190.5 million today). That deal boosted Daiichi Sankyo’s pipeline with U3 ...

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

(RTTNews) - Daiichi Sankyo (DSKYF.PK) and Merck & Co Inc. (MRK) said that they have reached a global development and commercialization agreement worth up to $22 billion for three of Daiichi Sankyo ...

Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22 billion.

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019, and DS-1062 (a TROP2 directed ADC) in July 2020 ...